MarketResearchReports.com: Social Gaming Market Entry and Success Strategy Analysis 2013, New Report Launched

The significant rise of social networks has created a springboard for the social gaming segment of the entertainment industry. Gaming is becoming increasingly compelling thanks to various enhancements such as the addition of socially playable and sharable features within games, which have gradually become common characteristics.

While generally a lucrative segment, the industry has its own challenges including short-term focus, low user retention, high CPA & OPEX, low ARPPU, and fragmented platforms.

This research evaluates the strategy of both successful and unsuccessful social gaming companies. Through this analysis, we have developed Success Guidelines for social gaming companies (start-up and established companies).

Target Audience:

  • Social network companies
  • Mobile application developers
  • Wireless infrastructure suppliers
  • OTT application and service providers
  • Social entertainment application developers
  • Wireless carriers and other service providers
  • Online, mobile, casual, and console game companies

Report Benefits:

  • Recognize how a strong value chain can mitigate social gaming risks to minimum
  • Understand features and strategic steps that are crucial for social gaming success
  • Identify how to create and introduce new compelling games vs. existing social games
  • Identify factors that drive success of social gaming companies and how others can learn from them
  • Identify the structure of a social gaming costs and how to keep marketing and acquisition budget low

Spanning over 31 pages and 7 figures, “Social Gaming Market Entry and Success Strategy Analysis 2013” report provides strategy of both successful and unsuccessful social gaming companies. For more information visit: http://www.marketresearchreports.com/mind-commerce/social-gaming-market-entry-and-success-strategy-analysis-2013

In addition to covering the Fetaures that need to incorporate with Social Game, Core Choices or Steps to Follow, Popular vs. New gaming IP: what to follow?, Costs Calcluation for 4 games series vs. 25-50% Success Case, Risks associated with Social Gaming Success, How to Create Successful Gaming IP line?, How to Minimize marketing & User Acquisition cost?, How to use Monetization Strategies?, How to Build Strong Development Chain?, Pretty Simple’s Criminal Case Lesson, Sojo Studio’s WETOPIA and JOY KINGDOM LESSON, KING.COM LESSON, ZYNGA LESSON.  The report covers 15 companies – 6waves, Bitcoin, Bitfold Games, Booyah, Facebook, King.com, Kontagent, Playdom, Playspan, Pretty Simple, Sojo Studios, Superewards, Trialpay, Ubisoft, Zynga.

Find all Computing and Electronics reports under a single page

Find all Entertainment and Gaming reports under a single page at: http://www.marketresearchreports.com/entertainment-gaming

About Market Research Reports, Inc.

Market Research Reports, Inc. (www.MarketResearchReports.com) is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

MarketResearchReports.com: Idiopathic Pulmonary Fibrosis (IPF) Market to Hit $1 Billion in 2017 – Opportunities for Pharma Companies Willing to Research

The idiopathic pulmonary fibrosis (IPF) therapy market across the US and EU will surpass $1 billion by 2017, and pharma companies could stand to benefit handsomely if they can add to the limited knowledge of the disease, states new analysis. For more information visit: OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) – Opportunity Analysis and Forecasts to 2017

The new research, “OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) – Opportunity Analysis and Forecasts to 2017”, states that over 70,000 people in the US and EU are thought to suffer from IPF, representing a commercially attractive patient population size with a financially appealing orphan drug status. So why has IPF been overlooked by the healthcare industry until the last decade?

Dr. Samantha Fernando, the report analyst covering Immunology, explains: “Future R&D strategies require the identification of critical biomarkers, so that disease progression and treatment response can be tracked – imperative to this is investment in research. The majority of existing knowledge on IPF has been captured by academics, and collaboration between academics and pharmaceutical companies is key to the advancement of this developing market. However, increased regulatory rigidness and extended trial duration is essential for this progressive disease, making drug development difficult. Approved medications also face a challenging economy, as increased emphasis is placed on the cost-effectiveness of drugs, particularly in the EU where various austerity measures are in place.”

The severely underserved market currently only has one licensed pharmacological treatment, InterMune’s Esbriet, an immunosuppressant with dual anti-fibrotic and anti-inflammatory properties licensed for use by the European Medicines Agency in 2011. However, despite being an orphan drug, it is not readily available across the region, due to its exorbitant price (>€22,000) relative to small therapeutic effect.

Analyst of this report expects IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise from $49m in 2012 to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6%. The EU has so far dominated the IPF market, but the US is set to reclaim market share in the future.

The IPF therapeutics market in the US is predicted to grow from a value of $6.5m in 2012 to $696m in 2017, at a Compound Annual Growth Rate (CAGR) of 154%. Dr. Fernando notes: “The anticipated launch of Esbriet and Nintedanib in 2015, to a market that previously had no therapeutic option will cause the US market to experience exponential growth, reaching nearly $500m in 2015 from only $19m in 2014. In contrast, the European IPF market was valued at a far stronger $43m in 2012, but is forecast to grow to $419m in 2017 at a CAGR of 58%.”

Spanning over 136 pages, 32 tables and 13 figures, “OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) – Opportunity Analysis and Forecasts to 2017” report develop business strategies by understanding the trends shaping and driving the global IPF therapeutics market.

In addition to covering the Disease Overview, Epidemiology, Current Treatment Options, Unmet Needs Assessment and Oppportunity Analysis, R&D Strategies and Pipeline Assessment, the report also presents pipeline valuation analysis for the Idiopathic Pulmonary Fibrosis (IPF).

Browse more Pharma and Healthcare market research reports.

About Market Research Reports, Inc.

Market Research Reports, Inc. (www.MarketResearchReports.com) is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.